Gynaecological cancer

Postgraduate Medical Journal

Volumn 75, Issue 884, 1999, Pages 332-338

  Kitchener, H C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer; Endometrial cancer; Ovarian cancer; Vulval cancer

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM;

CLINICAL TRIAL; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER; VULVA CANCER;

EID: 0032964386     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.75.884.332     Document Type: Review

References (24)

1. Department of Health. A policy framework for commissioning cancer services. Guidance for purchasers and providers of cancer services. London: Department of Health, May 1995.
2. Anon. A policy framework for commissioning cancer services. A joint Working Group response by the Royal College of Obstetricians and Gynaecologists and the British Gynaecological Cancer Society. London: RCOG Press, January 1997.
3. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Linkage Consortium. Am J Hum Genet 1993; 52:678-701.
4. Miki Y, Swenson J, Shatlock-Edens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
5. De Priest PD, Van Nagell JR, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51: 205.
6. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 1993;306:1030-4.
7. Jacobs I. Progress in screening for ovarian cancer. In: Sharp S, Blackett A, Bast R, eds, Progress in ovarian cancer. Oxford: Isis Medical Media, 1998; pp 173-85.
8. Bell R, Pettigrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. BrJ Obstet Gynaecol 1988;105:1136-47.
9. Neijt JP, Ten Bokkel Huinwink WW, Van der Berg MEL, et al. Long term survival in ovarian cancer: mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
10. Hunter RW, Alexander NDE, Soutter WP. Meta analysis of surgery in advanced ovarian carcinoma: is maximal cytoreductive surgery and independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-11.
11. Van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332:629-34.
12. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. N Engl J Med 1996;334:1-16.
13. Stuart G, Bertelsen K, Margioni C, et al. Updated analysis shows a highly significant improved overall survival for cisplatin/paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC - GCCG - NOCOVA NCIC CTG and Scottish Intergroup Trial. ASCO Proc 1998;17:361.
14. du Bois A, Richter B, Warm M, et al. Cisplatin/paclitaxel vs carboplatin as first line treatment in ovarian cancer.ASCO Proc 1998;17:361a.
15. Wallboomers JMM, de Roda Hussman AM, Snijders PJF, et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol 1995;48:728-32.
16. Cruickshank ME, Angus V, Kelly M, McPhee S, Kitchener HC. The case for stopping cervical screening at age 50. Br J Obstet Gynaecol 1997;104:586-9.
17. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage 1b-11a cervical cancer. Lancet 1997;350:535-40.
18. Hawnaur JM, Johnson RJ, Carrington BM, Hunter RD. Predictive value of clinical examination, transrectal ultrasound and magnetic resonance imaging prior to radiotherapy in carcinoma of the cervix. Br J Radiol 1998;71:819-27.
19. Shepherd JH, Crawford RAF, Oram DH. Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer. Br J Obstet Gynaecol 1998;105:912-6.
20. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
21. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in Stage 1 endometrial cancer. Obstet Gynecol 1980;58:419-27.
22. Creutzberg CL, van Putten W, Koper P, et al. Postoperative radiotherapy in stage I endometrial carcinoma: results from a prospective randomized trial of 715 patients (abstract). ESTRO, Edinburgh, 1998; no 307.
23. Iversen T, Abeler V, Aaiders J. Individualization of treatment for stage I squamous carcinoma of the vulva. Obstet Gynecol 1981;57:85.
24. Hacker NF, Berek JS, Lagasse LD. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 1984;63:155.